Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ICP-488 in Primary Sjögren's Syndrome
NCT07727486Phase 2Not yet recruiting
- Sponsor
- InnoCare Pharma
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of icp-488 in primary Sjögren's syndrome (4 arms), sponsored by InnoCare Pharma. Primary endpoint: Change from baseline in EULAR Sjögren's Syndrome Disease Activity Index at 24 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
icp-488
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT07727486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07727486.